CA2579338C - A topical medicament comprising menthol,camphor,potassium, and a source of oxygen - Google Patents
A topical medicament comprising menthol,camphor,potassium, and a source of oxygen Download PDFInfo
- Publication number
- CA2579338C CA2579338C CA2579338A CA2579338A CA2579338C CA 2579338 C CA2579338 C CA 2579338C CA 2579338 A CA2579338 A CA 2579338A CA 2579338 A CA2579338 A CA 2579338A CA 2579338 C CA2579338 C CA 2579338C
- Authority
- CA
- Canada
- Prior art keywords
- medicament
- weight
- oxygen
- source
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
- A61K31/125—Camphor; Nuclear substituted derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/748—Cyanobacteria, i.e. blue-green bacteria or blue-green algae, e.g. spirulina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/738—Rosa (rose)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/886—Aloeaceae (Aloe family), e.g. aloe vera
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
Abstract
New topical medicaments are provided. The medicaments comprise menthol and camphor, preferably provided as part of a base gel, supplemented with potassium and a source of oxygen. The most preferred base gel is sold under the name SOMBRA, while the most preferred source of oxygen is a chlorite (e.g., sodium chlorite) and/or spirulina. The medicaments provide high metabolic activities and sustain those activities over prolonged periods of time, thus being useful for treating a large variety of aliments, including diabetic neuropathy, post hepatic neuralgia, sclerodema, psoriasis, strain, spasticity, headaches, neuropathy secondary to drugs, peripheral neuropathy, leg pain, muscle cramps, muscle aches and pains, bruise, sinusitis, sprain, arthritis, joint pain (arthralgia), and edema.
Description
A TOPICAL MEDICAMENT COMPRISING MENTHOL, CAMPHOR, POTASSIUM, AND A SOURCE OF OXYGEN
BACKGROUND OF THE INVENTION
Field of the Invention The present invention is broadly concerned with improved topical medicaments in forms of creams or lotions which are useful in the treatment of a variety of conditions that are ameliorated by increased cell metabolism, circulation, and nerve function.
More particularly, the invention is concerned with such medicaments having a gel base with menthol and camphor, and supplemented with potassium and an oxygen source stich as an alkali metal chlorite.
Description of the Prior Art A variety of topically applied creams and lotions have been developed in the past for treatment of conditions such as arthritis and muscle pains. One such product is commercialized under the designation SOMBRA. This product contains 3% meMhol and 3% camphor, in a gel base, and is used for the temporary relief of minor aches aud pains of muscles and joints associated with simple backaches, arthritis, strains, brui es, and sprains.
However, many prior art creams and lotions do not adequately tre t these conditions in most people. Furthermore, even those that are successful do no sustain metabolic activity for extended periods of time, thus making any relief experiencCd rather temporary. There is a need for new treatments that provide relief for a wide variety of conditions and for extended periods of time.
SUMMARY OF THE INVENTION
The present invention overcomes these problems by broadly providing novel topical medicaments having improved metabolic activity.
BACKGROUND OF THE INVENTION
Field of the Invention The present invention is broadly concerned with improved topical medicaments in forms of creams or lotions which are useful in the treatment of a variety of conditions that are ameliorated by increased cell metabolism, circulation, and nerve function.
More particularly, the invention is concerned with such medicaments having a gel base with menthol and camphor, and supplemented with potassium and an oxygen source stich as an alkali metal chlorite.
Description of the Prior Art A variety of topically applied creams and lotions have been developed in the past for treatment of conditions such as arthritis and muscle pains. One such product is commercialized under the designation SOMBRA. This product contains 3% meMhol and 3% camphor, in a gel base, and is used for the temporary relief of minor aches aud pains of muscles and joints associated with simple backaches, arthritis, strains, brui es, and sprains.
However, many prior art creams and lotions do not adequately tre t these conditions in most people. Furthermore, even those that are successful do no sustain metabolic activity for extended periods of time, thus making any relief experiencCd rather temporary. There is a need for new treatments that provide relief for a wide variety of conditions and for extended periods of time.
SUMMARY OF THE INVENTION
The present invention overcomes these problems by broadly providing novel topical medicaments having improved metabolic activity.
In more detail, the inventive medicaments comprise menthol, camphor, potassium, and a source of oxygen. The menthol and camphor can be individually added to the composition, or they can be added via a base composition including menthol and camphor.
One preferred base composition is a gel sold under the name SOMBRA. Regardless of the delivery source, the menthol is preferably present in the medicament at a level of at least about 0.5% by weight, more preferably from about 2-20% by weight, and even more preferably from about 2-4% by weight, based upon the total weight of the medicament taken as 100% by weight. Furthermore, the camphor is preferably present in the medicament at a level of at least about 0.5% by weight, more preferably from about 2-20%
by weight, and even more preferably from about 2-4% by weight, based upon the total weight of the medicament taken as 100% by weight.
The potassium is preferably provided in powder form, and it can be obtained from dietary supplements, for example. One preferred source ofpotassium is Potassium Chelate (99 mg potency) sold by Nature's Way. Potassium Chelate is provided in the form of a capsule including powder potassium and minor amounts of ground millet. The capsule can simply be opened, and the powder from the capsule used in the present invention.
Potassium is preferably present in the medicament at a level of at least about 0.02% by weight, more preferably from about 0.04-0.5% by weight, and even more preferably from about 0.09-0.2% by weight, based upon the total weight of the medicament taken as 100%
by weight. When Potassium Chelate or a similar product is used, preferably from about 1-20 capsules, more preferably from about 1-15 capsules, and even more preferably from about 8-13 capsules are used.
The source of oxygen can be any source that is capable of delivering the appropriate levels of oxygen to the medicament. Suitable oxygen sources include those selected from the group consisting of chlorites (and preferably alkali metal chlorites such sodium chlorite and magnesium chlorite), spirulina, and mixtures of the foregoing. The most preferred oxygen source is sold under the name AEROBIC 07, which contains deionized water, sodium chlorite, carbonates, and bicarbonates.
The oxygen source is preferably present in the medicament in sufficient quantities to provide oxygen levels of at least about 0.016% by weight, more preferably from about 0.10-0.85% by weight, and even more preferably from about 0.17-0.25% by weight, based upon the total weight of the medicament taken as 100% by weight. When AEROBIC
or a similar product is used, it is preferably added at levels of from about 1-13 drops, more preferably from about 1-10 drops, and even more preferably about 4 drops.
In one alternative embodiment, the medicament also includes a source of chlorine ions. If sodium chlorite is used as the source of oxygen, it will also functions as a source of chlorine ions. Other suitable sources of chlorine ions include any chlorite (e.g., sodium hypochlorite) such as those found in commercially available bleaching agents (e.g., CLOROX, CALlBEX). In these embodiments, the source of chlorine is included in sufficient quantities to provide chlorine ion levels of from about 0.10-10% by weight, and more preferably from about 0.16-0.85% by weight, based upon the total weight of the medicament taken as 100% by weight.
The inventive medicaments can also include a number of optional ingredients, depending upon the final use. Some suitable ingredients include those selected from the group consisting of aloe vera extract, capsaicin, carbomer, decyl plyglucose, deionized water, grapefruit seed extract, green tea extract, orange peel extract, queen of the prairie extract, rose water, silica, sodium hydroxymethyl glycinate, vegetable glycerin, witch hazel, yucca extract, carbonates, bicarbonates, and mixtures of the foregoing.
The preferred quantities of these ingredients are set forth in Table 1. These ingredients can be added individually or in a group as part of another composition (e.g., in a base composition such as SOMBRA).
One preferred base composition is a gel sold under the name SOMBRA. Regardless of the delivery source, the menthol is preferably present in the medicament at a level of at least about 0.5% by weight, more preferably from about 2-20% by weight, and even more preferably from about 2-4% by weight, based upon the total weight of the medicament taken as 100% by weight. Furthermore, the camphor is preferably present in the medicament at a level of at least about 0.5% by weight, more preferably from about 2-20%
by weight, and even more preferably from about 2-4% by weight, based upon the total weight of the medicament taken as 100% by weight.
The potassium is preferably provided in powder form, and it can be obtained from dietary supplements, for example. One preferred source ofpotassium is Potassium Chelate (99 mg potency) sold by Nature's Way. Potassium Chelate is provided in the form of a capsule including powder potassium and minor amounts of ground millet. The capsule can simply be opened, and the powder from the capsule used in the present invention.
Potassium is preferably present in the medicament at a level of at least about 0.02% by weight, more preferably from about 0.04-0.5% by weight, and even more preferably from about 0.09-0.2% by weight, based upon the total weight of the medicament taken as 100%
by weight. When Potassium Chelate or a similar product is used, preferably from about 1-20 capsules, more preferably from about 1-15 capsules, and even more preferably from about 8-13 capsules are used.
The source of oxygen can be any source that is capable of delivering the appropriate levels of oxygen to the medicament. Suitable oxygen sources include those selected from the group consisting of chlorites (and preferably alkali metal chlorites such sodium chlorite and magnesium chlorite), spirulina, and mixtures of the foregoing. The most preferred oxygen source is sold under the name AEROBIC 07, which contains deionized water, sodium chlorite, carbonates, and bicarbonates.
The oxygen source is preferably present in the medicament in sufficient quantities to provide oxygen levels of at least about 0.016% by weight, more preferably from about 0.10-0.85% by weight, and even more preferably from about 0.17-0.25% by weight, based upon the total weight of the medicament taken as 100% by weight. When AEROBIC
or a similar product is used, it is preferably added at levels of from about 1-13 drops, more preferably from about 1-10 drops, and even more preferably about 4 drops.
In one alternative embodiment, the medicament also includes a source of chlorine ions. If sodium chlorite is used as the source of oxygen, it will also functions as a source of chlorine ions. Other suitable sources of chlorine ions include any chlorite (e.g., sodium hypochlorite) such as those found in commercially available bleaching agents (e.g., CLOROX, CALlBEX). In these embodiments, the source of chlorine is included in sufficient quantities to provide chlorine ion levels of from about 0.10-10% by weight, and more preferably from about 0.16-0.85% by weight, based upon the total weight of the medicament taken as 100% by weight.
The inventive medicaments can also include a number of optional ingredients, depending upon the final use. Some suitable ingredients include those selected from the group consisting of aloe vera extract, capsaicin, carbomer, decyl plyglucose, deionized water, grapefruit seed extract, green tea extract, orange peel extract, queen of the prairie extract, rose water, silica, sodium hydroxymethyl glycinate, vegetable glycerin, witch hazel, yucca extract, carbonates, bicarbonates, and mixtures of the foregoing.
The preferred quantities of these ingredients are set forth in Table 1. These ingredients can be added individually or in a group as part of another composition (e.g., in a base composition such as SOMBRA).
Table 1 INGREDIENT BROAD RANGEA MORE PREFERRED
RANGE' Aloe Vera Extract 0.10-50% 0.25-1.75%
Capsaicin 0.001-10% 0.25-1.75%
Carbomer 1.35-30% 2.75-19.25%
Decyl Plyglucose 0.1-9% 0.5-3.5%
Deionized Water 20-90% 76.5-90%
Grapefruit Seed Extract 0.001-5% 0.25-1.75%
Green Tea Extract 0.05-10% 0.5-3.5%
Orange Peel Extract 0.001-5% 0.25-1.75%
Queen of the Prairie Extract 0.25-20% 2.25-15.75%
Rose Water 0.2-7% 0.5-3.5%
Silica 0.03-20% 1-7%
Sodium Hydroxymethyl 0.05-25% 1.25-8.75%
Glycinate Vegetable Glycerin 0.09-50% 1.75-12.25%
Witch Hazel 0.02-15% 1-7%
Yucca Extract 0.015-30% 0.5-3.5%
Carbonates 0.025-3.5 % 0.25-1.75%
Bicarbonates 0.025-3.5% 0.25-1.75%
A The percentages by weight are based upon the total weight of the topical medicament taken as 100% by weight.
The inventive medicaments are formed by simply mixing the above ingredients together, preferably in some type of carrier. If SOMBRA is used, then the carrier is provided by that product.
In a particularly preferred preparation method, a precursor composition containing the camphor and menthol is provided. The precursor composition should comprise:
from about 1-10% by weight menthol, preferably from about 1-5%
menthol, and even more preferably about 3% by weight menthol;
and from about 1-10% by weight camphor, preferably from about 1-5%
RANGE' Aloe Vera Extract 0.10-50% 0.25-1.75%
Capsaicin 0.001-10% 0.25-1.75%
Carbomer 1.35-30% 2.75-19.25%
Decyl Plyglucose 0.1-9% 0.5-3.5%
Deionized Water 20-90% 76.5-90%
Grapefruit Seed Extract 0.001-5% 0.25-1.75%
Green Tea Extract 0.05-10% 0.5-3.5%
Orange Peel Extract 0.001-5% 0.25-1.75%
Queen of the Prairie Extract 0.25-20% 2.25-15.75%
Rose Water 0.2-7% 0.5-3.5%
Silica 0.03-20% 1-7%
Sodium Hydroxymethyl 0.05-25% 1.25-8.75%
Glycinate Vegetable Glycerin 0.09-50% 1.75-12.25%
Witch Hazel 0.02-15% 1-7%
Yucca Extract 0.015-30% 0.5-3.5%
Carbonates 0.025-3.5 % 0.25-1.75%
Bicarbonates 0.025-3.5% 0.25-1.75%
A The percentages by weight are based upon the total weight of the topical medicament taken as 100% by weight.
The inventive medicaments are formed by simply mixing the above ingredients together, preferably in some type of carrier. If SOMBRA is used, then the carrier is provided by that product.
In a particularly preferred preparation method, a precursor composition containing the camphor and menthol is provided. The precursor composition should comprise:
from about 1-10% by weight menthol, preferably from about 1-5%
menthol, and even more preferably about 3% by weight menthol;
and from about 1-10% by weight camphor, preferably from about 1-5%
5 camphor, and even more preferably about 3% by weight camphor, based upon the total weight of the medicament taken as 100% by weight.
The precursor composition can also include some or all of the optional ingredients discussed above.
A quantity of the precursor composition is added to a container, along with a portion of the potassium. Further respective quantities of the precursor composition and potassium are then added in alternating steps until the desired quantity as been obtained.
The precursor composition and potassium within the container are preferably then mixed until substantially homogeneous (e.g., from about 1-3 minutes, and preferably about 2 minutes). Mixing can be carried out by hand or mechanical mixing means (e.g., mixer, shearing in industrial equipment). The source of oxygen is then added to the resulting mixture and further mixing is carried out. Any optional ingredients that were not already added can then be added to the mixture to yield the final medicament.
The inventive topical medicament is used to treat a portion of the body (human or animal) afflicted with an ailment by simply contacting the medicament with the afflicted portion of the body. The medicament is then preferably rubbed into the skin until it is no longer visible. It will be appreciated that the medicament can be used to treat numerous conditions, including diabetic neuropathy, post hepatic neuralgia, scleroderma, psoriasis, strain, spasticity, headaches, neuropathy secondary to drugs, peripheral neuropathy, leg pain, muscle cramps, muscle aches and pains, bruise, sinusitis, sprain, arthritis, joint pain (arthralgia), and edema.
The inventive medicament offers a particularly significant advantage in that it achieves high metabolic activity and maintains that activity over extended periods of time.
"Metabolic activity" as used herein refers to energy (in mV) that is created by the potassium ions in the medicament. That energy is then transferred to the patient at the medicament location on the skin. Though not wishing to be bound by theory, it is believed that the energy excites and thus opens the sodium-potassium pumps in the cells. This stimulates the nervous system and better allows active ingredients to enter the cells.
Metabolic activity is determined by mixing 1 g of a medicament with 0.1 g of a commercially available electrolyte material (e.g., one sold under the name ORAL
REHYDRATION SALTS, available from Jianas Bros. Packaging Co.). The mixture is then placed onto an electrogel pad, which is "sandwiched" between two ECG
patches connected to a voltmeter. Readings in mV are taken over regular intervals (e.g., 5-minute intervals).
When using the medicaments of the invention, a peak (i.e., highest or maximum) metabolic activity of at least about 2.5 mV, preferably at least about 4 mV, and more preferably from about 4-20 mV is achieved. This peak is preferably achieved within about 30 minutes, and more preferably within about 15 minutes, of application to the afflicted area.
The inventive medicaments also possess the property of having a retained metabolic activity of at least about 20%, preferably at least about 30%, and even more preferably from about 50-100% over a 45-minute time period. Furthermore, the inventive medicaments possess the property of having a retained metabolic activity of at least about 5%, preferably at least about 20%, and even more preferably from about 25-100%
over an 8-hour time period. As used herein, "retained metabolic activity" is determined as follows:
metabolic activity after 45 minutes or 8 hours Retained Metabolic Activity = _____________________________ x 100 peak metabolic activity BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 a is a graph depicting the metabolic activity of a prior art product over a 45-minute time period;
The precursor composition can also include some or all of the optional ingredients discussed above.
A quantity of the precursor composition is added to a container, along with a portion of the potassium. Further respective quantities of the precursor composition and potassium are then added in alternating steps until the desired quantity as been obtained.
The precursor composition and potassium within the container are preferably then mixed until substantially homogeneous (e.g., from about 1-3 minutes, and preferably about 2 minutes). Mixing can be carried out by hand or mechanical mixing means (e.g., mixer, shearing in industrial equipment). The source of oxygen is then added to the resulting mixture and further mixing is carried out. Any optional ingredients that were not already added can then be added to the mixture to yield the final medicament.
The inventive topical medicament is used to treat a portion of the body (human or animal) afflicted with an ailment by simply contacting the medicament with the afflicted portion of the body. The medicament is then preferably rubbed into the skin until it is no longer visible. It will be appreciated that the medicament can be used to treat numerous conditions, including diabetic neuropathy, post hepatic neuralgia, scleroderma, psoriasis, strain, spasticity, headaches, neuropathy secondary to drugs, peripheral neuropathy, leg pain, muscle cramps, muscle aches and pains, bruise, sinusitis, sprain, arthritis, joint pain (arthralgia), and edema.
The inventive medicament offers a particularly significant advantage in that it achieves high metabolic activity and maintains that activity over extended periods of time.
"Metabolic activity" as used herein refers to energy (in mV) that is created by the potassium ions in the medicament. That energy is then transferred to the patient at the medicament location on the skin. Though not wishing to be bound by theory, it is believed that the energy excites and thus opens the sodium-potassium pumps in the cells. This stimulates the nervous system and better allows active ingredients to enter the cells.
Metabolic activity is determined by mixing 1 g of a medicament with 0.1 g of a commercially available electrolyte material (e.g., one sold under the name ORAL
REHYDRATION SALTS, available from Jianas Bros. Packaging Co.). The mixture is then placed onto an electrogel pad, which is "sandwiched" between two ECG
patches connected to a voltmeter. Readings in mV are taken over regular intervals (e.g., 5-minute intervals).
When using the medicaments of the invention, a peak (i.e., highest or maximum) metabolic activity of at least about 2.5 mV, preferably at least about 4 mV, and more preferably from about 4-20 mV is achieved. This peak is preferably achieved within about 30 minutes, and more preferably within about 15 minutes, of application to the afflicted area.
The inventive medicaments also possess the property of having a retained metabolic activity of at least about 20%, preferably at least about 30%, and even more preferably from about 50-100% over a 45-minute time period. Furthermore, the inventive medicaments possess the property of having a retained metabolic activity of at least about 5%, preferably at least about 20%, and even more preferably from about 25-100%
over an 8-hour time period. As used herein, "retained metabolic activity" is determined as follows:
metabolic activity after 45 minutes or 8 hours Retained Metabolic Activity = _____________________________ x 100 peak metabolic activity BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 a is a graph depicting the metabolic activity of a prior art product over a 45-minute time period;
Fig. lb is a graph depicting the metabolic activity of another prior art product over a 45-minute time period;
Fib. lc is a graph depicting the metabolic activity of the inventive medicament over a 45-minute time period; and Fig. ld is a graph depicting the metabolic activity of the inventive medicament over an 8-hour time period.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
EXAMPLES
The following examples set forth preferred methods in accordance with the invention. It is to be understood, however, that these examples are provided by way of illustration and nothing therein should be taken as a limitation upon the overall scope of the invention.
Preparation of Topical Medicament A 1-gallon plastic jug was tared on a Sunbeam Model SP5 top balance (no shield, small pan balance). The jug was then charged with 5.7 oz of SOMBRA Natural Pain Relieving Gel (available from Sombra Inc., Albuquerque, NM).
Thirteen potassium amino acid chelate capsules (99 mg potassium with millet filler;
available from Nature's Way, Springville, UT) were emptied three at a time.
The filled capsule weight was 0.78 g, the emptied powder weight was 0.67 g, and the empty capsule weight was 0.67 g (n=1). The level of elemental potassium in the capsule was not given on the label.
The powder emptied from the capsules was then added to the SOMBRA in the plastic jug as follows:
(1) The jug was charged with SOMBRA to a weight of 12.1 oz., and the powder from three empty capsules was added;
Fib. lc is a graph depicting the metabolic activity of the inventive medicament over a 45-minute time period; and Fig. ld is a graph depicting the metabolic activity of the inventive medicament over an 8-hour time period.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
EXAMPLES
The following examples set forth preferred methods in accordance with the invention. It is to be understood, however, that these examples are provided by way of illustration and nothing therein should be taken as a limitation upon the overall scope of the invention.
Preparation of Topical Medicament A 1-gallon plastic jug was tared on a Sunbeam Model SP5 top balance (no shield, small pan balance). The jug was then charged with 5.7 oz of SOMBRA Natural Pain Relieving Gel (available from Sombra Inc., Albuquerque, NM).
Thirteen potassium amino acid chelate capsules (99 mg potassium with millet filler;
available from Nature's Way, Springville, UT) were emptied three at a time.
The filled capsule weight was 0.78 g, the emptied powder weight was 0.67 g, and the empty capsule weight was 0.67 g (n=1). The level of elemental potassium in the capsule was not given on the label.
The powder emptied from the capsules was then added to the SOMBRA in the plastic jug as follows:
(1) The jug was charged with SOMBRA to a weight of 12.1 oz., and the powder from three empty capsules was added;
(2) The jug was charged with SOMBRA to a weight of 1 lb. 6.1 oz., and the powder from three empty capsules was added;
(3) The jug was charged with SOMBRA to a weight of 2 lb. 3.9 oz., and the powder from the remaining empty capsules was added; and (4) The jug was charged to a final weight of 3 lb. 1 oz. with SOMBRA.
A cap was placed on the jug, and the jug was shaken by hand for about 2 minutes to substantially evenly distribute the powder. The gel did not adhere to the plastic jug after the potassium amino acid chelate was added.
AEROBIC 07 (a dietary supplement including deionized water, sodium chlorite, carbonates, and bicarbonates; available from Aerobic Live, Phoenix, AZ) was used as a stabilized source of oxygen. Thirteen drops of the Aerobic 07 were added to the plastic jug containing the SOMBRA-potassium amino acid chelate mixture. The jug was again capped and shaken by hand for about 2 minutes to yield the final topical medicament. The final medicament was more viscous than the SOMBRA gel. When comparing a quantity of each, the compounded medicament did not separate or flow as compared to the SOMBRA gel, which showed some physical separation.
Treatment of Patient A
1. Patient History The topical medicament prepared in Example 1 was used to treat a patient (hereinafter referred to as "Patient A"). Patient A was a Caucasian female in her 60s, and she was 5'7" and approximately 220 lb. Patient A exhibited neuropathy of the legs and feet, with the left leg being worse than the right. Patient A's big toe on her right foot and second toe on her left foot were amputated within the preceding 3 years due to diabetes.
She had received angioplasty about 9 months prior, and the angioplasty improved blood flow to her lower extremities.
Both legs below the knees presented open sores about half-way between the knee caps and ankles. The sores were worse on the right leg than the left. She had used Bactroban and Betadine to treat the topical sores for infection.
(3) The jug was charged with SOMBRA to a weight of 2 lb. 3.9 oz., and the powder from the remaining empty capsules was added; and (4) The jug was charged to a final weight of 3 lb. 1 oz. with SOMBRA.
A cap was placed on the jug, and the jug was shaken by hand for about 2 minutes to substantially evenly distribute the powder. The gel did not adhere to the plastic jug after the potassium amino acid chelate was added.
AEROBIC 07 (a dietary supplement including deionized water, sodium chlorite, carbonates, and bicarbonates; available from Aerobic Live, Phoenix, AZ) was used as a stabilized source of oxygen. Thirteen drops of the Aerobic 07 were added to the plastic jug containing the SOMBRA-potassium amino acid chelate mixture. The jug was again capped and shaken by hand for about 2 minutes to yield the final topical medicament. The final medicament was more viscous than the SOMBRA gel. When comparing a quantity of each, the compounded medicament did not separate or flow as compared to the SOMBRA gel, which showed some physical separation.
Treatment of Patient A
1. Patient History The topical medicament prepared in Example 1 was used to treat a patient (hereinafter referred to as "Patient A"). Patient A was a Caucasian female in her 60s, and she was 5'7" and approximately 220 lb. Patient A exhibited neuropathy of the legs and feet, with the left leg being worse than the right. Patient A's big toe on her right foot and second toe on her left foot were amputated within the preceding 3 years due to diabetes.
She had received angioplasty about 9 months prior, and the angioplasty improved blood flow to her lower extremities.
Both legs below the knees presented open sores about half-way between the knee caps and ankles. The sores were worse on the right leg than the left. She had used Bactroban and Betadine to treat the topical sores for infection.
Patient A also had an ulcer on the bottom of her right foot. She had begun a second, 2-3 week treatment course of Regranex, applying at bedtime. Previous use of Regranex had worked, but the ulcer recurred, so she then had surgery. She began to use Etherex, which she stated is a generic medicine for Regranex and Bactroban.
Her daily medications are shown in Table A-B.
Table A
PRESCRIPTION MEDICATION DOSAGE
Lisinopril 20/12.5 2 p.o. qd Atenolol 50 mg 1 1/2 p.o. qd Lipitor 40 mg 1 p.o. qd Insulin 40u of N and 10u of Humalog in morning;
40u of N and 10u of Humalog before dinner Paroxitine (Paxil) 40 mg p.o. qd Levothyroxine 0.3 mg p.o. qd Calcitrol 0.25 p.g 1 p.o. bid Niaspan 500 mg 1 p.o. q evening Plavix 75 mg 1 p.o. qd Furosemide 80 mg p.o. 1 daily Diovan 320 mg 1 daily Procrit 1 injection q 2 weeks until no longer needed Dynacirc 5 mg 1 p.o. daily Table B
VITAMINS AND OVER-THE- DOSAGE
COUNTER MEDICATIONS
Multivitamin 1 p.o. daily 5 Prilosec 1 p.o. daily Low-Dose Aspirin 1 every evening Iron 2 "pills" each day for anemia Patient A also reported using Walitin (generic for Claritin) and Nasonex as needed 10 for allergies.
2. Treatment with Inventive Topical Medicament The ambient temperature during treatment ranged from 74-78 F according to measurements from four different Stress Thermometers used "as is" (Dr.
Lowenstein's Model SC911 accuracy +/- 1.8 F, 10 ft. lead with fast temperature sensor).
Patient A was recumbent on a treatment table with a triangular pillow positioned behind both knees so that the knees were bent upward to rise above the ankles.
A
temperature probe was strapped on each upper ventral thigh and on the inside of each ankle. The probes were covered, and no medicament was applied to the probes.
Equilibration time was approximately 10 minutes after the patient reclined in the prone position. After equilibration time was reached, the temperatures were recorded as shown in Table C.
Table C
PROBE LOCATION TEMPERATURE
right thigh 90.0 F
left ankle 86.7 F
right thigh 92.3 F
right ankle 90.1 F
Her daily medications are shown in Table A-B.
Table A
PRESCRIPTION MEDICATION DOSAGE
Lisinopril 20/12.5 2 p.o. qd Atenolol 50 mg 1 1/2 p.o. qd Lipitor 40 mg 1 p.o. qd Insulin 40u of N and 10u of Humalog in morning;
40u of N and 10u of Humalog before dinner Paroxitine (Paxil) 40 mg p.o. qd Levothyroxine 0.3 mg p.o. qd Calcitrol 0.25 p.g 1 p.o. bid Niaspan 500 mg 1 p.o. q evening Plavix 75 mg 1 p.o. qd Furosemide 80 mg p.o. 1 daily Diovan 320 mg 1 daily Procrit 1 injection q 2 weeks until no longer needed Dynacirc 5 mg 1 p.o. daily Table B
VITAMINS AND OVER-THE- DOSAGE
COUNTER MEDICATIONS
Multivitamin 1 p.o. daily 5 Prilosec 1 p.o. daily Low-Dose Aspirin 1 every evening Iron 2 "pills" each day for anemia Patient A also reported using Walitin (generic for Claritin) and Nasonex as needed 10 for allergies.
2. Treatment with Inventive Topical Medicament The ambient temperature during treatment ranged from 74-78 F according to measurements from four different Stress Thermometers used "as is" (Dr.
Lowenstein's Model SC911 accuracy +/- 1.8 F, 10 ft. lead with fast temperature sensor).
Patient A was recumbent on a treatment table with a triangular pillow positioned behind both knees so that the knees were bent upward to rise above the ankles.
A
temperature probe was strapped on each upper ventral thigh and on the inside of each ankle. The probes were covered, and no medicament was applied to the probes.
Equilibration time was approximately 10 minutes after the patient reclined in the prone position. After equilibration time was reached, the temperatures were recorded as shown in Table C.
Table C
PROBE LOCATION TEMPERATURE
right thigh 90.0 F
left ankle 86.7 F
right thigh 92.3 F
right ankle 90.1 F
The inventive medicament was applied to the top and bottom of each thigh and later (as shown in Table D) to the top and bottom of each calf, ankle, and foot. The product was massaged into the skin until nearly invisible to the eye. The dosage level was 0.3 oz. on each thigh and each ankle for a total per leg dosage of 0.6 oz.
Temperature readings were taken at intervals, beginning 5 minutes after application to Patient A's legs. These readings are set forth in Table D.
Table D
TIME LOCATION TEMPERATURE ( F) 5 minutes' left thigh 90.5 left ankle 86.9 right thigh 92.3 right ankle 90.9 Note - Patient A reported feeling heat at 5 minutes.
7 minutes left thigh 90.9 left ankle 86.9 right thigh 92.3 right ankle 90.9 10 minutes left thigh 91.5 left ankle 86.9 right thigh 92.5 right ankle 91.2 Note - Patient A reported heat at same level as at 5 minutes.
15 minutes left thigh 91.4 left ankle 87.1 TIME LOCATION TEMPERATURE ( F) right thigh 92.1 right ankle 90.7 Note - Patient A reported feeling a warm sensation. There was sweat behind the left knee. Medicament was applied to left ankle at 17 minutes. A paper towel was placed on the triangular pillow.
20 minutes left thigh 91.2 left ankle 86.7 right thigh 91.9 right ankle 90.1 25 minutes left thigh 91.2 left ankle 86.5 right thigh 91.8 right ankle 90.3 30 minutes left thigh 91.2 left ankle 86.9 right thigh 91.6 right ankle 90.3 35 minutes left thigh 91.6 left ankle 86.9 right thigh 91.8 right ankle 90.5 Note - Medicament was applied to right ankle at 35 minutes.
40 minutes left thigh 91.4 TIME LOCATION TEMPERATURE ( F) left ankle 86.9 right thigh 90.3 right ankle 90.5 45 minutes left thigh 91.2 left ankle 86.9 right thigh 88.7 right ankle 90.1 50 minutes left thigh 91.2 left ankle 86.4 right thigh 89.2 right ankle 90.5 55 minutes left thigh 91.2 left ankle 87.3 right thigh 89.4 right ankle 90.1 Note - At 57 minutes, Patient A reported a cool feeling from above the ankle to the heel.
60 minutes left thigh 91.4 left ankle 87.3 right thigh 90.0 right ankle 90.1 65 minutes left thigh 91.2 TIME LOCATION TEMPERATURE ( F) left ankle 87.4 right thigh 90.5 right ankle 90.5 70 minutes left thigh 91.0 left ankle 87.3 right thigh 90.7 right ankle 90.1 Five minutes after application to left calf and lower thigh (0 time).
Patient A rose from the table at 78 minutes, and the thigh probes were removed.
Patient A held the readout portion of the thermometers in her hand while the probes were still attached to the ankles to allow her to walk to the restroom and take a further readout of her ankles after 5 minutes elapsed. However, at 82 minutes the left ankle probe came loose so no reading was taken. The right ankle probe gave a reading of 81.1 F
at 82 minutes. Patient A reported that her left side (neuropathic side) felt soothed.
Treatment of Patient B
1. Patient History The topical medicament prepared in Example 1 was used to treat a second patient (hereinafter referred to as "Patient B"). Patient B was a 60-year old, 5'7", Caucasian female. She was a non-insulin dependent diabetic and had sensory neuropathy that was worse in her right leg. She did not have any visible wounds. Her daily oral medications were Glucophage (1 in the evening), Toprol, Diovan, and Lipitor (1 in the evening).
2. Treatment with Inventive Topical Medicament The ambient temperature during treatment ranged from 74-75 F according to measurements from the four different Stress Thermometers as described in Part 2 of Example 2. The probes were applied as described in Part 2 of Example 2. The initial 5 readings are shown in Table E.
Table E
PROBE LOCATION TEMPERATUREA TEMPERATUREc left thigh 88.7 F 89.1 F
10 left ankle 83.8 F 83.8 F
right thigh 79.0 FB 90.7 F
right ankle 86.5 F 86.5 F
A Temperature prior to medicament application.
B The probe came loose from the right thigh, thus resulting in the 79 F
reading.
Temperature readings were taken at intervals, beginning 5 minutes after application to Patient A's legs. These readings are set forth in Table D.
Table D
TIME LOCATION TEMPERATURE ( F) 5 minutes' left thigh 90.5 left ankle 86.9 right thigh 92.3 right ankle 90.9 Note - Patient A reported feeling heat at 5 minutes.
7 minutes left thigh 90.9 left ankle 86.9 right thigh 92.3 right ankle 90.9 10 minutes left thigh 91.5 left ankle 86.9 right thigh 92.5 right ankle 91.2 Note - Patient A reported heat at same level as at 5 minutes.
15 minutes left thigh 91.4 left ankle 87.1 TIME LOCATION TEMPERATURE ( F) right thigh 92.1 right ankle 90.7 Note - Patient A reported feeling a warm sensation. There was sweat behind the left knee. Medicament was applied to left ankle at 17 minutes. A paper towel was placed on the triangular pillow.
20 minutes left thigh 91.2 left ankle 86.7 right thigh 91.9 right ankle 90.1 25 minutes left thigh 91.2 left ankle 86.5 right thigh 91.8 right ankle 90.3 30 minutes left thigh 91.2 left ankle 86.9 right thigh 91.6 right ankle 90.3 35 minutes left thigh 91.6 left ankle 86.9 right thigh 91.8 right ankle 90.5 Note - Medicament was applied to right ankle at 35 minutes.
40 minutes left thigh 91.4 TIME LOCATION TEMPERATURE ( F) left ankle 86.9 right thigh 90.3 right ankle 90.5 45 minutes left thigh 91.2 left ankle 86.9 right thigh 88.7 right ankle 90.1 50 minutes left thigh 91.2 left ankle 86.4 right thigh 89.2 right ankle 90.5 55 minutes left thigh 91.2 left ankle 87.3 right thigh 89.4 right ankle 90.1 Note - At 57 minutes, Patient A reported a cool feeling from above the ankle to the heel.
60 minutes left thigh 91.4 left ankle 87.3 right thigh 90.0 right ankle 90.1 65 minutes left thigh 91.2 TIME LOCATION TEMPERATURE ( F) left ankle 87.4 right thigh 90.5 right ankle 90.5 70 minutes left thigh 91.0 left ankle 87.3 right thigh 90.7 right ankle 90.1 Five minutes after application to left calf and lower thigh (0 time).
Patient A rose from the table at 78 minutes, and the thigh probes were removed.
Patient A held the readout portion of the thermometers in her hand while the probes were still attached to the ankles to allow her to walk to the restroom and take a further readout of her ankles after 5 minutes elapsed. However, at 82 minutes the left ankle probe came loose so no reading was taken. The right ankle probe gave a reading of 81.1 F
at 82 minutes. Patient A reported that her left side (neuropathic side) felt soothed.
Treatment of Patient B
1. Patient History The topical medicament prepared in Example 1 was used to treat a second patient (hereinafter referred to as "Patient B"). Patient B was a 60-year old, 5'7", Caucasian female. She was a non-insulin dependent diabetic and had sensory neuropathy that was worse in her right leg. She did not have any visible wounds. Her daily oral medications were Glucophage (1 in the evening), Toprol, Diovan, and Lipitor (1 in the evening).
2. Treatment with Inventive Topical Medicament The ambient temperature during treatment ranged from 74-75 F according to measurements from the four different Stress Thermometers as described in Part 2 of Example 2. The probes were applied as described in Part 2 of Example 2. The initial 5 readings are shown in Table E.
Table E
PROBE LOCATION TEMPERATUREA TEMPERATUREc left thigh 88.7 F 89.1 F
10 left ankle 83.8 F 83.8 F
right thigh 79.0 FB 90.7 F
right ankle 86.5 F 86.5 F
A Temperature prior to medicament application.
B The probe came loose from the right thigh, thus resulting in the 79 F
reading.
15 c Temperature at 4 minutes after temperature reading in middle column.
Temperature readings were taken as described in Part 2 of Example 2. These readings and the times of medicament application to Patient B's legs are set forth in Table F.
Table F
TIME LOCATION TEMPERATURE ( F) 5 minutesA
left thigh 90.5 left ankle 81.5 right thigh 91.6 right ankle 86.2 Note - The inventive medicament was applied to the entire left leg at 5 minutes. At 7 minutes, Patient B reported that her left leg was cool.
10 minutes left thigh 90.5 TIME LOCATION TEMPERATURE ( F) left ankle 81.5 right thigh 91.9 right ankle 85.8 15 minutes left thigh 90.7 left ankle 81.5 right thigh 92.3 right ankle 85.8 20 minutes left thigh 90.9 left ankle 81.1 -right thigh 92.1 right ankle 85.5 Note - Patient B reported feeling a stinging sensation behind her left knee, and that the toes on her left foot felt strange.
minutes left thigh 91.0 left ankle 81.1 right thigh 92.3 20 right ankle 84.7 Note - Patient B reported that she still felt a stinging sensation behind her left knee.
minutes left thigh 91.6 left ankle 81.1 25 right thigh 92.8 right ankle 84.7 TIME LOCATION TEMPERATURE ( F) 35 minutes left thigh 91.6 left ankle 81.1 right thigh 93.0 right ankle 82.9 Note - The inventive medicament was applied to the entire right leg at 35 minutes.
40 minutes left thigh 91.9 left ankle 81.0 right thigh 93.6 right ankle 83.3 45 minutes left thigh 92.1 left ankle 80.6 right thigh 93.6 right ankle 83.7 Note - Patient B reported feeling a burning on her left side. She stated that her right leg felt cool, and that she felt a sensation as if a thumb were being pressed into the middle of the arch on her right foot. She reported that she had a stress fracture of the calchaneal bone on the right heel.
50 minutes left thigh 91.9 left ankle 80.2 right thigh 93.6 right ankle 83.7 Note - Patient B reported that she thought the doctor was touching her right foot, but he was not.
Temperature readings were taken as described in Part 2 of Example 2. These readings and the times of medicament application to Patient B's legs are set forth in Table F.
Table F
TIME LOCATION TEMPERATURE ( F) 5 minutesA
left thigh 90.5 left ankle 81.5 right thigh 91.6 right ankle 86.2 Note - The inventive medicament was applied to the entire left leg at 5 minutes. At 7 minutes, Patient B reported that her left leg was cool.
10 minutes left thigh 90.5 TIME LOCATION TEMPERATURE ( F) left ankle 81.5 right thigh 91.9 right ankle 85.8 15 minutes left thigh 90.7 left ankle 81.5 right thigh 92.3 right ankle 85.8 20 minutes left thigh 90.9 left ankle 81.1 -right thigh 92.1 right ankle 85.5 Note - Patient B reported feeling a stinging sensation behind her left knee, and that the toes on her left foot felt strange.
minutes left thigh 91.0 left ankle 81.1 right thigh 92.3 20 right ankle 84.7 Note - Patient B reported that she still felt a stinging sensation behind her left knee.
minutes left thigh 91.6 left ankle 81.1 25 right thigh 92.8 right ankle 84.7 TIME LOCATION TEMPERATURE ( F) 35 minutes left thigh 91.6 left ankle 81.1 right thigh 93.0 right ankle 82.9 Note - The inventive medicament was applied to the entire right leg at 35 minutes.
40 minutes left thigh 91.9 left ankle 81.0 right thigh 93.6 right ankle 83.3 45 minutes left thigh 92.1 left ankle 80.6 right thigh 93.6 right ankle 83.7 Note - Patient B reported feeling a burning on her left side. She stated that her right leg felt cool, and that she felt a sensation as if a thumb were being pressed into the middle of the arch on her right foot. She reported that she had a stress fracture of the calchaneal bone on the right heel.
50 minutes left thigh 91.9 left ankle 80.2 right thigh 93.6 right ankle 83.7 Note - Patient B reported that she thought the doctor was touching her right foot, but he was not.
TIME LOCATION TEMPERATURE ( F) 55 minutes left thigh 91.9 left ankle 80.1 right thigh 93.7 right ankle 83.3 Note - Patient B reported that her left leg was feeling restless.
60 minutes left thigh 92.7 left ankle 80.1 right thigh 93.9 right ankle 83.3 65 minutes left thigh 93.0 left ankle 80.1 right thigh 94.1 right ankle 83.3 Note - Patient B rose at 66 minutes.
70 minutes left thigh 91.0 left ankle 79.7 right thigh 91.0 right ankle 82.8 A Five minutes after first temperature reading in Table E.
The probes were removed after 70 minutes.
60 minutes left thigh 92.7 left ankle 80.1 right thigh 93.9 right ankle 83.3 65 minutes left thigh 93.0 left ankle 80.1 right thigh 94.1 right ankle 83.3 Note - Patient B rose at 66 minutes.
70 minutes left thigh 91.0 left ankle 79.7 right thigh 91.0 right ankle 82.8 A Five minutes after first temperature reading in Table E.
The probes were removed after 70 minutes.
Determination of Metabolic Activity The topical medicament prepared in Example 1 was applied to the left inner forearm (below the elbow) of a patient. The treated area was then swabbed with a glass slide that was subsequently sandwiched between two ECG patches attached to leads to a Radio Shack digital, multi-meter. The initial reading (time =0) was 0.0 mV.
Subsequent readings were taken at different intervals, and those results are reported in Table G.
Table G
TIME READING
(minutes after initial reading) (mV) 1 0.2 32 0.9 33 0.8 43 0.9 51 1.0 52 0.9 56 1.0 72 1.2 73 1.4 74 1.2 121 1.5 This test was carried out to show that oxygen activation from the compounded medicament occurs following the application to human skin with or without sweat.
This test was repeated using medicament that had been swabbed from another patient's back. However, the cream turned green in color and did not reproduce similar results with the ECG patches. It also took about 6 hours and 20 minutes for this person to notice the heat activation in the location where the medicament had been applied to the back.
Metabolic Activity Comparison In this test, the metabolic activity of the topical medicament prepared in Example 1 was determined following the steps set forth in Example 4. The same steps were 5 followed to determine the metabolic activity of two prior art products.
Fig. la shows the metabolic activity of one prior art product (non-modified SOMBRA) over a 45-minute time period. Fig. lb shows the metabolic activity of another prior art product (non-modified BIO-FREEZE) over a 45-minute time period. Fig. 1 c shows the inventive medicament's metabolic activity over a 45-minute time period. A comparison of these 10 figures shows that metabolic activity of the prior art peaks and then drops substantially over the 45-minute time period while the inventive medicament's metabolic activity maintains very high levels even after peaking. Fig. id shows the inventive medicament's metabolic activity over an 8-hour time period. This graph shows that this activity drops slowly over the 8-hour time period, thus providing prolonged treatment periods as 15 compared to prior art products.
Treatment of Patient with Inventive Topical Medicament The patient in this example (hereinafter referred to as "Patient C") was a Caucasian 20 female in her late 50s. Patient C was suffering from neuropathy in her feet, with symptoms including sharp, stabbing pains and contractures due to over-stimulation of muscles. The condition had caused Patient C to take disability from work.
The topical medicament prepared in Example 1 was applied to Patient C's feet.
Within 10 minutes, the contractures in her feet started to release, and she reported that her feet felt 90% better. Also, the sharp, stabbing pain was relieved for 6 hours after treatment.
Subsequent readings were taken at different intervals, and those results are reported in Table G.
Table G
TIME READING
(minutes after initial reading) (mV) 1 0.2 32 0.9 33 0.8 43 0.9 51 1.0 52 0.9 56 1.0 72 1.2 73 1.4 74 1.2 121 1.5 This test was carried out to show that oxygen activation from the compounded medicament occurs following the application to human skin with or without sweat.
This test was repeated using medicament that had been swabbed from another patient's back. However, the cream turned green in color and did not reproduce similar results with the ECG patches. It also took about 6 hours and 20 minutes for this person to notice the heat activation in the location where the medicament had been applied to the back.
Metabolic Activity Comparison In this test, the metabolic activity of the topical medicament prepared in Example 1 was determined following the steps set forth in Example 4. The same steps were 5 followed to determine the metabolic activity of two prior art products.
Fig. la shows the metabolic activity of one prior art product (non-modified SOMBRA) over a 45-minute time period. Fig. lb shows the metabolic activity of another prior art product (non-modified BIO-FREEZE) over a 45-minute time period. Fig. 1 c shows the inventive medicament's metabolic activity over a 45-minute time period. A comparison of these 10 figures shows that metabolic activity of the prior art peaks and then drops substantially over the 45-minute time period while the inventive medicament's metabolic activity maintains very high levels even after peaking. Fig. id shows the inventive medicament's metabolic activity over an 8-hour time period. This graph shows that this activity drops slowly over the 8-hour time period, thus providing prolonged treatment periods as 15 compared to prior art products.
Treatment of Patient with Inventive Topical Medicament The patient in this example (hereinafter referred to as "Patient C") was a Caucasian 20 female in her late 50s. Patient C was suffering from neuropathy in her feet, with symptoms including sharp, stabbing pains and contractures due to over-stimulation of muscles. The condition had caused Patient C to take disability from work.
The topical medicament prepared in Example 1 was applied to Patient C's feet.
Within 10 minutes, the contractures in her feet started to release, and she reported that her feet felt 90% better. Also, the sharp, stabbing pain was relieved for 6 hours after treatment.
Claims (18)
1. A topical medicament for treating diabetic neuropathy comprising at least 0.5% by weight menthol and at least 0.5% by weight camphor, said medicament further comprising 0.02-0.5% by weight potassium and a source of oxygen present at sufficient levels to provide an oxygen level of from 0.016%-0.85% by weight, the percentages by weight being based upon the total weight of the medicament taken as 100% by weight.
2. The medicament of claim 1, wherein said medicament is in the form of a gel.
3 The medicament of claim 1 or claim 2, wherein said source of oxygen is selected from the group consisting of chlorites, spirulina, and mixtures of the foregoing.
4. The medicament of claim 3, wherein said source of oxygen is an alkali metal chlorite.
5. The medicament of any one of claims 1 to 4, wherein said medicament further comprises an ingredient selected from the group consisting of aloe vera extract, capsaicin, carbomer, decyl polyglucose, deionized water, grapefruit seed extract, green tea extract, orange peel extract, queen of the prairie extract, rose water, silica, sodium hydroxymethyl glycinate, vegetable glycerin, witch hazel, yucca extract, carbonates, bicarbonates, and mixtures of the foregoing.
6. The medicament of any one of claims 1 to 5, wherein said medicament has a retained metabolic activity of at least 20% over a 45-minute time period.
7. The medicament of any one of claims 1 to 5, wherein said medicament has a retained metabolic activity of at least 5% over an 8-hour time period.
8. Use of a medicament for treating a portion of a body afflicted with diabetic neuropathy, said medicament comprising at least 0.5% by weight menthol, at least 0.5% by weight camphor, from 0.02-0.5% by weight potassium, and a source of oxygen present at sufficient levels to provide an oxygen level of from 0.016-0.85% by weight, the percentages by weight being based upon the total weight of the medicament taken as 100% by weight.
9. The use of claim 8, wherein said medicament is administrable by rubbing said medicament into the portion of the body afflicted with diabetic neuropathy.
10. The use of claim 8 or claim 9, wherein said medicament is in the form of a gel.
11. The use of any one of claims 8 to 10, wherein said source of oxygen is selected from the group consisting of chlorites, spirulina, and mixtures of the foregoing.
12. The use of claim 11, wherein said source of oxygen is an alkali metal chlorite.
13. The use of any one of claims 8 to 12, wherein said medicament further comprises an ingredient selected from the group consisting of aloe vera extract, capsaicin, carbomer, decyl polyglucose, deionized water, grapefruit seed extract, green tea extract, orange peel extract, queen of the prairie extract, rose water, silica, sodium hydroxymethyl glycinate, vegetable glycerin, witch hazel, yucca extract, and mixtures of the foregoing.
14. The use of any one of claims 8 to 13, wherein said medicament has a retained metabolic activity of at least 20% over a 45-minute time period after administration.
15. The use of any one of claims 8 to 13, wherein said medicament has a retained metabolic activity of at least 5% over an 8-hour time period after administration.
16. A method of preparing a topical medicament, said method comprising the step of mixing together at least 0.5% by weight menthol, at least 0.5% by weight camphor, from 0.02-0.5% by weight potassium, and a source of oxygen present at sufficient levels to provide an oxygen level of from 0.016-0.85% by weight, the percentages by weight being based upon the total weight of the medicament taken as 100% by weight.
17. The method of claim 16, wherein said method further comprises the steps of:
(a) providing a precursor composition comprising said menthol and camphor;
(b) adding said potassium to a quantity of said precursor composition to yield a first intermediate composition;
(c) alternately adding further quantities of said precursor composition and said potassium to said first intermediate composition to form a second intermediate composition; and (d) adding said source of oxygen to said second intermediate composition to yield the topical medicament.
(a) providing a precursor composition comprising said menthol and camphor;
(b) adding said potassium to a quantity of said precursor composition to yield a first intermediate composition;
(c) alternately adding further quantities of said precursor composition and said potassium to said first intermediate composition to form a second intermediate composition; and (d) adding said source of oxygen to said second intermediate composition to yield the topical medicament.
18.
The method of claim 17, further comprising the step of mixing said second intermediate composition prior to adding step (d).
The method of claim 17, further comprising the step of mixing said second intermediate composition prior to adding step (d).
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60813604P | 2004-09-08 | 2004-09-08 | |
US60/608,136 | 2004-09-08 | ||
US11/220,138 | 2005-09-06 | ||
US11/220,138 US7704522B2 (en) | 2004-09-08 | 2005-09-06 | Topical medicament |
PCT/US2005/031819 WO2006029189A2 (en) | 2004-09-08 | 2005-09-07 | Topical medicament |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2579338A1 CA2579338A1 (en) | 2006-03-16 |
CA2579338C true CA2579338C (en) | 2014-07-08 |
Family
ID=35996542
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2579338A Expired - Fee Related CA2579338C (en) | 2004-09-08 | 2005-09-07 | A topical medicament comprising menthol,camphor,potassium, and a source of oxygen |
Country Status (5)
Country | Link |
---|---|
US (3) | US7704522B2 (en) |
AU (1) | AU2005282502B2 (en) |
CA (1) | CA2579338C (en) |
GB (1) | GB2432314B (en) |
WO (1) | WO2006029189A2 (en) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7704522B2 (en) * | 2004-09-08 | 2010-04-27 | Clyde Morgan | Topical medicament |
US7811554B2 (en) | 2007-01-19 | 2010-10-12 | Flavio Lozano | Horse liniment |
EP2121048B9 (en) | 2007-02-19 | 2016-02-24 | Marine Polymer Technologies, Inc. | Hemostatic compositions and therapeutic regimens |
WO2009006701A1 (en) * | 2007-07-12 | 2009-01-15 | Peter O'gorman | Topical medicament |
EP2042167A1 (en) * | 2007-09-26 | 2009-04-01 | Aisa Therapeutics | Use of a monoterpene to induce tissue repair |
US20110021958A1 (en) * | 2009-07-27 | 2011-01-27 | Lynds Bruce G | Therapeutic Devices And Methods Of Using The Same |
CN107412772A (en) | 2010-04-15 | 2017-12-01 | 海洋聚合物技术公司 | The antibacterial applications of poly- N acetylglucosamines nanofiber |
EP2696680B1 (en) * | 2011-04-15 | 2018-11-28 | Marine Polymer Technologies, Inc. | Treatment of hsv infections with poly-n-acetyl glucosamine nanofibers |
US20130072575A1 (en) * | 2011-09-19 | 2013-03-21 | Johnson & Johnson Consumer Companies, Inc. | Method and Composition for Treating Pain |
US9717757B1 (en) | 2011-12-28 | 2017-08-01 | Samuel N. Gasque, Jr. | Composition and method to treat and prevent muscle cramping |
WO2014193972A1 (en) * | 2013-05-29 | 2014-12-04 | Kirkpatrick Melissa | Topical examination compositions and methods |
US10154984B2 (en) * | 2015-07-01 | 2018-12-18 | Twi Biotechnology, Inc. | Diacerein or Rhein topical formulations and uses thereof |
KR20180023965A (en) | 2015-07-01 | 2018-03-07 | 티더블유아이 바이오테크놀로지 인코포레이티드 | Diacerein or rhein topical formulations and uses thereof |
US10512625B2 (en) * | 2015-07-01 | 2019-12-24 | Twi Biotechnology, Inc. | Diacerein or rhein topical formulations and uses thereof |
CN106620154A (en) * | 2015-11-03 | 2017-05-10 | 聂金莲 | Impediment pain plaster |
US10265079B2 (en) * | 2016-04-28 | 2019-04-23 | Grena Usa Llc | Polymeric ligating clip |
US20240075112A1 (en) * | 2020-11-25 | 2024-03-07 | Topix Pharmaceuticals, Inc. | Scar treatment composition |
Family Cites Families (82)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2045618B (en) * | 1979-04-03 | 1983-05-11 | Hisamitsu Pharmaceutical Co | Adhesive plaster |
DE3213389A1 (en) * | 1982-04-10 | 1983-10-20 | Friedrich-Wilhelm Dr. 7107 Neckarsulm Kühne | STABILIZED ACTIVATED OXYGEN AND MEDICINAL PRODUCTS CONTAINING THIS STABILIZED ACTIVATED OXYGEN |
DE3344691A1 (en) * | 1983-12-10 | 1985-06-20 | Bayer Ag, 5090 Leverkusen | ACTIVE GAS EXHAUST SYSTEMS |
DE3347278A1 (en) * | 1983-12-28 | 1985-07-11 | Bayer Ag, 5090 Leverkusen | ACTIVE SUBSTANCE DELIVERY SYSTEMS |
DE3347277A1 (en) * | 1983-12-28 | 1985-07-11 | Bayer Ag, 5090 Leverkusen | ACTIVE SUBSTANCE DELIVERY SYSTEMS |
DE3409079A1 (en) * | 1984-03-13 | 1985-09-19 | Bayer Ag, 5090 Leverkusen | MEDICAL PLASTER |
US4892890A (en) * | 1984-11-01 | 1990-01-09 | G. D. Searle And Company | External analgesic compositions |
LU85643A1 (en) * | 1984-11-16 | 1986-06-04 | Oreal | THERMAL-SLIMMING COSMETIC COMPOSITION BASED ON OLEOSOLUBLE PLANT EXTRACTS |
JPS61293911A (en) * | 1985-06-24 | 1986-12-24 | Teisan Seiyaku Kk | Sustained release preparation |
US4702916A (en) * | 1985-12-03 | 1987-10-27 | Warner-Lambert Company | Analgesic stick compositions |
US4963591A (en) * | 1985-12-16 | 1990-10-16 | Carter-Wallace Inc. | Cosmetic compositions |
US5145675A (en) * | 1986-03-31 | 1992-09-08 | Advanced Polymer Systems, Inc. | Two step method for preparation of controlled release formulations |
JPS62169723A (en) * | 1986-01-22 | 1987-07-25 | Teisan Seiyaku Kk | Sustained release preparation |
DE3704907A1 (en) * | 1987-02-17 | 1988-08-25 | Bayer Ag | TOPICALLY APPLICABLE PREPARATIONS OF GYRASE INHIBITORS IN COMBINATION WITH CORTICOSTEROIDS |
EP0484530B1 (en) * | 1989-07-28 | 1995-07-12 | Hisamitsu Pharmaceutical Co., Inc. | Foamed aerosol preparation |
US5383848A (en) * | 1990-04-12 | 1995-01-24 | Gensia, Inc. | Iontophoretic administration of drugs |
US5273754A (en) * | 1992-03-27 | 1993-12-28 | Mann Morris A | Appetite suppressant composition and method relating thereto |
US5429590A (en) * | 1992-12-01 | 1995-07-04 | Nitto Denko Corporation | Medical water-absorptive polymer and dressing for wound and medical bandage using the same |
HUT67748A (en) * | 1993-07-27 | 1995-04-28 | Biogal Gyogyszergyar | Hair tonic composition |
DE4341444C2 (en) * | 1993-12-04 | 1996-03-14 | Lohmann Therapie Syst Lts | Active substance-containing plaster and process for its production |
US5505958A (en) * | 1994-10-31 | 1996-04-09 | Algos Pharmaceutical Corporation | Transdermal drug delivery device and method for its manufacture |
US5597849A (en) * | 1994-11-14 | 1997-01-28 | Medical Polymer Technologies, Inc. | Stick formulations for topical drug delivery of therapeutic agents and uses thereof |
US5804203A (en) * | 1994-12-21 | 1998-09-08 | Cosmederm Technologies | Topical product formulations containing strontium for reducing skin irritation |
US6139850A (en) * | 1994-12-21 | 2000-10-31 | Cosmederm Technologies | Formulations and methods for reducing skin irritation |
US5716625A (en) * | 1994-12-21 | 1998-02-10 | Cosmederm Technologies | Formulations and methods for reducing skin irritation |
IT1275955B1 (en) * | 1995-03-22 | 1997-10-24 | Dompe Spa | PHARMACEUTICAL FORMULATIONS IN THE FORM OF THISSOTROPIC GEL |
US5866143A (en) * | 1995-03-24 | 1999-02-02 | El Khoury And Stein, Ltd. | Topical application of opioid drugs such as morphine for relief of itching and skin disease |
HU213450B (en) * | 1995-04-26 | 1997-06-30 | Ladanyi Jozsef | Gel contains gelatin and process for producing it |
US5665386A (en) * | 1995-06-07 | 1997-09-09 | Avmax, Inc. | Use of essential oils to increase bioavailability of oral pharmaceutical compounds |
US5716928A (en) * | 1995-06-07 | 1998-02-10 | Avmax, Inc. | Use of essential oils to increase bioavailability of oral pharmaceutical compounds |
CA2224227A1 (en) * | 1995-06-07 | 1996-12-19 | Avmax, Inc. | Use of essential oils to increase bioavailability of oral pharmaceutical compounds |
EP0750905B1 (en) * | 1995-06-27 | 2003-01-02 | Kao Corporation | Patch comprising water soluble adhesive sheet |
US5626856A (en) * | 1995-06-30 | 1997-05-06 | Safe & Dry Company, Inc. | Cosmetic delivery vehicles and related compositions |
US5882663A (en) * | 1995-10-20 | 1999-03-16 | Koeniger; Erich A. | Topical pain-relieving preparation containing C12 To C18 isoparaffins |
US6239180B1 (en) * | 1995-11-08 | 2001-05-29 | The Regents Of The University Of California | Transdermal therapeutic device and method with capsaicin and capsaicin analogs |
US5855922A (en) * | 1995-12-07 | 1999-01-05 | Bio-Cide International, Inc. | Antiseptic composition and process for prophylaxis and therapeutic treatment of dermal disorders |
TW452494B (en) * | 1996-03-12 | 2001-09-01 | Jang De Shan | Herbal composition for stimulating blood circulation |
US5716621A (en) * | 1996-07-03 | 1998-02-10 | Pharmadyn, Inc. | Nonocclusive drug delivery device and process for its manufacture |
US5955067A (en) * | 1996-07-23 | 1999-09-21 | Oge; Eray | Potassium-containing composition useful in the treatment of acne, psoriasis and seborrhea |
US5916548A (en) * | 1996-09-04 | 1999-06-29 | The Procter & Gamble Company | Personal care compositions |
US5830447A (en) * | 1996-09-04 | 1998-11-03 | The Procter & Gamble Company | Personal care compositions |
US5863527A (en) * | 1996-09-04 | 1999-01-26 | The Proctor & Gamble Company | Personal care compositions |
US5804173A (en) * | 1996-09-04 | 1998-09-08 | The Procter & Gamble Company | Personal care compositions |
US6440987B1 (en) * | 1996-11-25 | 2002-08-27 | Toray Industries, Inc. | Antipruritic |
US6174891B1 (en) * | 1996-11-25 | 2001-01-16 | Toray Industries, Inc. | Antipruritic agent |
US6645506B1 (en) * | 1997-04-18 | 2003-11-11 | Ganeden Biotech, Inc. | Topical compositions containing extracellular products of Pseudomonas lindbergii and Emu oil |
JP2002514221A (en) * | 1997-05-27 | 2002-05-14 | アルゴス ファーマシューティカル コーポレーション | Analgesic composition containing capsaicinoid and enhancer thereof |
JP4677063B2 (en) * | 1997-07-18 | 2011-04-27 | 帝國製薬株式会社 | Dutch mustard extract combination external preparation |
DE19749467C2 (en) * | 1997-11-08 | 1999-09-23 | Beiersdorf Ag | Active substance-containing patches |
US5980925A (en) * | 1997-12-30 | 1999-11-09 | Ethicon, Inc. | High glycerin containing anti-microbial cleansers |
US6103266A (en) * | 1998-04-22 | 2000-08-15 | Tapolsky; Gilles H. | Pharmaceutical gel preparation applicable to mucosal surfaces and body tissues |
EP1002810A4 (en) * | 1998-06-04 | 2002-07-17 | Kao Corp | Polymer emulsion and process for producing the same |
US6284234B1 (en) * | 1998-08-04 | 2001-09-04 | Johnson & Johnson Consumer Companies, Inc. | Topical delivery systems for active agents |
JP4017758B2 (en) * | 1998-08-04 | 2007-12-05 | 高砂香料工業株式会社 | Cooling agent composition |
US6258857B1 (en) * | 1999-02-04 | 2001-07-10 | Kyowa Industrial Co., Ltd. | Internal liquid composition contained as internal liquid in a releasing container and releasing container product |
US6277401B1 (en) * | 1999-05-07 | 2001-08-21 | U.S. Dermatologics, Inc. | Drug delivery device |
US6495498B2 (en) * | 1999-05-27 | 2002-12-17 | Johnson & Johnson Consumer Companies, Inc. | Detergent compositions with enhanced depositing, conditioning and softness capabilities |
US6524594B1 (en) * | 1999-06-23 | 2003-02-25 | Johnson & Johnson Consumer Companies, Inc. | Foaming oil gel compositions |
US6335023B1 (en) * | 1999-06-30 | 2002-01-01 | Ruey J. Yu | Oligosaccharide aldonic acids and their topical use |
JP3724988B2 (en) * | 1999-07-30 | 2005-12-07 | 信越化学工業株式会社 | Novel silicone compound and cosmetic comprising the same |
US6306412B1 (en) * | 1999-08-13 | 2001-10-23 | Unilever Home & Personal Care Usa, Division Of Conopco, Inc. | Cosmetic strip with an agent for inducing a temperature change |
US6270783B1 (en) * | 1999-08-13 | 2001-08-07 | Unilever Home & Personal Care Usa, Division Of Conopco, Inc. | Cosmetic strips with liquid crystal temperature dependent color change |
US6653352B2 (en) * | 1999-09-29 | 2003-11-25 | Medical Merchandising, Inc. | Pain reliever and method of use |
US6348218B1 (en) * | 1999-10-04 | 2002-02-19 | Invent Resources, Inc. | Self dosing skin preparation |
US6586000B2 (en) * | 1999-12-16 | 2003-07-01 | Dermatrends, Inc. | Hydroxide-releasing agents as skin permeation enhancers |
US6645520B2 (en) * | 1999-12-16 | 2003-11-11 | Dermatrends, Inc. | Transdermal administration of nonsteroidal anti-inflammatory drugs using hydroxide-releasing agents as permeation enhancers |
US6582724B2 (en) * | 1999-12-16 | 2003-06-24 | Dermatrends, Inc. | Dual enhancer composition for topical and transdermal drug delivery |
US6432415B1 (en) * | 1999-12-17 | 2002-08-13 | Axrix Laboratories, Inc. | Pharmaceutical gel and aerosol formulations and methods to administer the same to skin and mucosal surfaces |
DE10001546A1 (en) * | 2000-01-14 | 2001-07-19 | Beiersdorf Ag | Process for the continuous production and coating of self-adhesive compositions based on polyisobutylene with at least one active pharmaceutical ingredient |
US6635702B1 (en) * | 2000-04-11 | 2003-10-21 | Noveon Ip Holdings Corp. | Stable aqueous surfactant compositions |
US6623756B1 (en) * | 2000-04-27 | 2003-09-23 | Noveon Ip Holdings Corp. | Directly compressed solid dosage articles |
US6409997B1 (en) * | 2000-07-31 | 2002-06-25 | Neutrogena Corporation | Wax cosmetic stick |
US6433061B1 (en) * | 2000-10-24 | 2002-08-13 | Noveon Ip Holdings Corp. | Rheology modifying copolymer composition |
AU2002236775A1 (en) * | 2001-01-16 | 2002-07-30 | Seok-Ki Choi | Sodium channel modulators |
NZ526453A (en) * | 2001-01-31 | 2005-01-28 | Pfizer Prod Inc | Nicotinamide biaryl derivatives useful as inhibitors of PDE4 isozymes |
KR20030072614A (en) * | 2001-01-31 | 2003-09-15 | 화이자 프로덕츠 인크. | Thiazolyl-, Oxazolyl-, Pyrrolyl-, and Imidazolyl-Acid Amide Derivatives Useful as Inhibitors of PDE4 Isozymes |
US6589568B2 (en) | 2001-02-16 | 2003-07-08 | Nurad, Inc. | Therapeutic body lotion containing alkali metal hypohalite |
US6592896B2 (en) * | 2001-08-06 | 2003-07-15 | The Quigley Corporation | Medicinal composition and method of using it |
US6596313B2 (en) * | 2001-08-06 | 2003-07-22 | The Quigley Corporation | Nutritional supplement and methods of using it |
US6638981B2 (en) * | 2001-08-17 | 2003-10-28 | Epicept Corporation | Topical compositions and methods for treating pain |
US6579543B1 (en) * | 2002-02-22 | 2003-06-17 | Jackie H. McClung | Composition for topical application to skin |
US7704522B2 (en) | 2004-09-08 | 2010-04-27 | Clyde Morgan | Topical medicament |
-
2005
- 2005-09-06 US US11/220,138 patent/US7704522B2/en not_active Expired - Fee Related
- 2005-09-07 AU AU2005282502A patent/AU2005282502B2/en not_active Ceased
- 2005-09-07 GB GB0704141A patent/GB2432314B/en not_active Expired - Fee Related
- 2005-09-07 WO PCT/US2005/031819 patent/WO2006029189A2/en active Application Filing
- 2005-09-07 CA CA2579338A patent/CA2579338C/en not_active Expired - Fee Related
-
2007
- 2007-10-03 US US11/866,573 patent/US8541034B2/en not_active Expired - Fee Related
-
2008
- 2008-09-18 US US12/233,444 patent/US8048447B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US7704522B2 (en) | 2010-04-27 |
WO2006029189A3 (en) | 2007-05-03 |
CA2579338A1 (en) | 2006-03-16 |
US8541034B2 (en) | 2013-09-24 |
US20080069903A1 (en) | 2008-03-20 |
US20060051432A1 (en) | 2006-03-09 |
US20090017138A1 (en) | 2009-01-15 |
AU2005282502B2 (en) | 2011-01-27 |
GB2432314A (en) | 2007-05-23 |
WO2006029189A2 (en) | 2006-03-16 |
GB2432314B (en) | 2009-10-28 |
AU2005282502A1 (en) | 2006-03-16 |
GB0704141D0 (en) | 2007-04-11 |
US8048447B2 (en) | 2011-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2579338C (en) | A topical medicament comprising menthol,camphor,potassium, and a source of oxygen | |
AU2008266971B2 (en) | Topical composition for treating pain | |
TWI345470B (en) | Homeopathic formulations useful for treating pain and/or inflammation | |
CA2554860A1 (en) | Pharmaceutical composition and method for the transdermal delivery of magnesium | |
JP5622775B2 (en) | Composition for treating dermatosis, formulation using the same, and preparation method thereof | |
EP3369428A1 (en) | External traditional chinese medicine preparation for diminishing inflammation, relieving pain and promoting fast healing, and preparation method therefor | |
CA2730009C (en) | Topical medicament | |
EP0841895B1 (en) | Slimming cream based on plants | |
US20180169071A1 (en) | Nutritional supplement composition | |
KR20050067837A (en) | Composition for slimming | |
CN115531446A (en) | Application of composition in preparing medicine for diminishing inflammation, relieving pain and healing wound | |
CA2446254C (en) | New synergetic compositions of vitamins, minerals and trace-elements to stimulate the elimination of intra-cellular lipid deposits | |
US20160101141A1 (en) | Topical Treatment of Sports Related Injuries | |
CN101904958A (en) | Oral medicinal composition for treating fracture | |
US20180338906A1 (en) | Composition for transdermal delivery of glutathione | |
KR20020066242A (en) | A herb medicine for treating an arthritis | |
AU2008274908B2 (en) | Topical medicament | |
WO2017201624A1 (en) | Composition for transdermal delivery of glutathione | |
RU2170097C2 (en) | Cedar nut curative spirituous tincture and method of its using | |
US11717493B2 (en) | Cannabidiol compositions for the treatment of inflammation | |
US20210038669A1 (en) | Composition(s) for Topically Treating Pain | |
US20240091290A1 (en) | Pharmaceutical composition for relieving pain from joint and muscle strain | |
KR20200131787A (en) | Lymphatic circulation promotive food composition | |
CN101926922B (en) | Chinese patent medicament for treating cerebrovascular diseases and preparation method thereof | |
RU2287997C1 (en) | Composition for treating inflammatory diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20200908 |